{"id":"W4386388190","doi":"10.1016/j.eururo.2023.08.010","title":"Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]","year":2023,"lang":"en","type":"erratum","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Axitinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004973519,0.001482248,0.002811248,0.0007586358,0.0002700293,0.00002424455,0.001111682,0.0004671266,0.0005130402],"category_scores_gemma":[0.0006456603,0.001110761,0.001176325,0.00105152,0.000403904,0.00005165171,0.0007276578,0.001169489,0.0008203364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000803835,"about_ca_system_score_gemma":0.001255302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008948027,"about_ca_topic_score_gemma":0.0009522606,"domain_scores_codex":[0.9921756,0.001473149,0.001972016,0.00182687,0.001242092,0.001310305],"domain_scores_gemma":[0.9937613,0.0005033668,0.001416766,0.003120621,0.0006050915,0.0005928383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1634126,0.01648137,0.001477684,0.001196576,0.004098746,0.0286794,0.0108887,0.001182941,0.003011153,0.00004987906,0.7580345,0.01148648],"study_design_scores_gemma":[0.1505705,0.1679741,0.0229789,0.0002117918,0.006854602,0.0002900199,0.0009796491,0.0001146571,0.004612113,0.00001073884,0.6441928,0.001210128],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8169277,0.003527853,0.00001237565,0.0009010767,0.04299882,0.005953585,0.001192803,0.0002237237,0.1282621],"genre_scores_gemma":[0.7392147,0.0003011502,0.00003730994,0.0002425021,0.001538478,0.0001957949,0.001470656,0.0004562067,0.2565432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1514927,"threshold_uncertainty_score":0.9999576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05649958729501037,"score_gpt":0.3012588737262299,"score_spread":0.2447592864312195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}